The week's stories
All 81 stories from the week's issues, by topic.
Clinical trials
- Toripalimab combination improved event-free survival in pancreatic cancerStory 11
- Surgery had lower death rates than radiotherapy for early-stage lung cancerStory 12
- Botensilimab and balstilimab met response goal in colon cancer trialStory 14
- Shorter radiation matched standard control in high-risk breast cancerStory 22
- Dinutuximab with induction chemotherapy was feasible for high-risk neuroblastomaStory 23
- Short-course radiation matched standard care before pancreatic cancer surgeryStory 27
- Niraparib shrank advanced ovarian cancer before surgery in a phase II trialStory 28
- Pembrolizumab delays womb cancer growth in first-line trialStory 36
- Wake Forest names breast cancer specialist to lead new departmentStory 39
- Osimertinib combination improved survival in advanced non-small cell lung cancerStory 51
- SBRT matched surgery for localized prostate cancer controlStory 52
- HB0025 and chemotherapy shrank tumors in advanced non-small cell lung cancerStory 53
- Izalontamab brengitecan slowed advanced non-small cell lung cancerStory 70
Antibody-drug conjugates
- Durvalumab combination improved outcomes in muscle-invasive bladder cancerStory 8
- Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialStory 18
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Story 19
- Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell LymphomaStory 32
- Izalontamab brengitecan delayed breast cancer growth in a phase III trialStory 35
- Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction ImmunochemotherapyStory 45
- Ruzaltatug rezetecan delayed lung cancer growth in a phase III trialStory 49
- Drug combination improves control of metastatic breast cancerStory 54
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Story 59
- Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer antibody-drug conjugate TherapyStory 61
- Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaStory 77
Cell and gene therapy
- Removing GALE boosted immune cell killing in colorectal cancer modelsStory 1
- Blocking BAZ2A restored engineered immune cells in mouse kidney cancerStory 2
- Breast cancer screening found fewer interval cancers, but the difference was not significantStory 9
- Two drug combinations offer second-line options for follicular lymphomaStory 10
- Cell therapy showed early signs of activity in melanomaStory 24
- Allogeneic Cell Therapy in Refractory T-Cell LymphomaStory 60
- MTAP loss linked to immunotherapy response in pleural mesotheliomaStory 73
Precision oncology
- Study links genetic changes to relapse in childhood acute lymphoblastic leukemiaStory 13
- Blood tests identified high-risk Ewing sarcoma patientsStory 37
- Ivonescimab showed tumor responses in resectable lung cancer trialStory 38
- Researchers mapped varied cells in glioblastomaStory 41
- Ponatinib and blinatumomab improve outcomes in acute lymphoblastic leukemiaStory 69
- Experts to discuss chest CT screening for lung cancerStory 72
Head and neck cancer
- Deferred radiotherapy did not lower survival in metastatic nasopharyngeal cancerStory 6
- FDA approves Rybrevant Faspro for head and neck squamous cell carcinomaStory 62
- FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaStory 63
- FDA approves amivantamab for previously treated head and neck cancerStory 78
- FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCCStory 80
India access
- Assam signs Rs 600 crore deal for India's first state-run proton therapy centreStory 7
- Shilpa CDMO invests $50 million to expand peptide manufacturing capacityStory 48
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Story 67
- Trends in Racial and Ethnic Representation in the Oncology Trainee WorkforceStory 68
Cancer vaccines
- Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)Story 20
- RNA vaccine boosted engineered T cells against glioblastoma in lab modelsStory 40
- RNA Vaccination Drives Expansion and Brain-Licensing of T Cells to Enhance the Efficacy of Adoptive Cell Therapy in GlioblastomaStory 46
AI and cancer
Radiopharmaceuticals
Cancer-care delivery
Radioligands
Other
- Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as CAR T cell target for pediatric solid tumorsStory 3
- Tissue architecture and immune niches govern circulating tumour DNA release in colorectal cancerStory 4
- Deep learning integration of ultrasound perfusion and stiffness maps predicts tumor response to treatmentStory 5
- The First African Genome and the Search for Answers on Prostate Cancer DisparitiesStory 15
- Genome-anchored foundation model embeddings improve molecular prediction from histology imagesStory 16
- Targeting hypersialylation in pancreatic cancer microfluidic models reverses its malignant phenotype and enhances CAR-T therapyStory 17
- Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerStory 21
- HER2-Positive Targeted Therapy Cardiovascular Risk: ACC Upcoming Journal ClubStory 29
- The AACR Grantee Summit 2026: Fueling Discovery and Fostering ConnectionStory 30
- Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab VedotinStory 31
- USP54 regulates RIPK1 protein abundance via deubiquitination in acquired sorafenib resistance in hepatocellular carcinomaStory 33
- Evaluation of Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes.Story 34
- Perlmutter Cancer Center Names Director of Early-Phase Drug Development and Rare Cancer ProgramsStory 42
- In vivo CAR-T double knockout screen maps synergistic antitumour gene pairsStory 43
- Cancer-specific T cell receptor discovery using 150,000 clinical genomics samplesStory 44
- A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentStory 47
- FDA grants accelerated approval to Rybrevant Faspro for head and neck cancerStory 50
- Trends in Racial and Ethnic Representation in the Oncology Trainee WorkforceStory 56
- Integrated Whole-Genome and Transcriptome Sequencing Reveals Divergent Evolutionary Processes Across Biliary Tract Cancer SubtypesStory 57
- Spatiotemporal control of CAR-T cell TNF release via tumor-targeted irradiationStory 58
- Acquired resistance to vorinostat in cutaneous T cell lymphoma involves augmented ERK phosphorylationStory 64
- A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisStory 65
- CT-95 in Advanced Cancers Associated With Mesothelin ExpressionStory 66
- FDA approves amivantamab for head and neck cancerStory 71
- Patient-Provider Communication, Treatment, and Survival in a Population-Based Cohort: The North Carolina-Louisiana Prostate Cancer ProjectStory 75
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerStory 81